WO2016131321A1 - Nadph在制备治疗心脑血管疾病的药物中的应用 - Google Patents
Nadph在制备治疗心脑血管疾病的药物中的应用 Download PDFInfo
- Publication number
- WO2016131321A1 WO2016131321A1 PCT/CN2015/095392 CN2015095392W WO2016131321A1 WO 2016131321 A1 WO2016131321 A1 WO 2016131321A1 CN 2015095392 W CN2015095392 W CN 2015095392W WO 2016131321 A1 WO2016131321 A1 WO 2016131321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nadph
- thrombosis
- cardiovascular
- cerebrovascular diseases
- atherosclerosis
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
- NADPH在制备治疗或预防心脑血管疾病药物中的应用。
- 根据权利要求1所述的应用,其特征在于,所述心脑血管疾病是指血栓病、高血压、冠心病、血管硬化、动脉粥样硬化中的一种。
- 根据权利要求2所述的应用,其特征在于,所述血栓病、高血压、冠心病、血管硬化、动脉粥样硬化是指由血管内皮细胞损伤导致的血栓病、高血压、冠心病、血管硬化、动脉粥样硬化。
- 根据权利要求2或3中所述的应用,其特征在于,所述血栓病是指动脉血栓、静脉血栓中的一种。
- NADPH在制备保护血管内皮细胞、维护血管正常通透性的药物中的应用。
- 根据权利要求1-5中任一所述的应用,其特征在于,所述药物包括药学上有效量的NADPH和药学上可接受的载体。
- 一种用于治疗或预防心脑血管疾病的药物,其特征在于,所述药物以NADPH为活性成分,向NADPH中加入常规辅料按照常规工艺制成临床上可接受的合剂、胶囊剂、片剂、药膜剂、喷雾剂。
- 一种用于治疗或预防血栓病、高血压、冠心病、血管硬化、动脉粥样硬化中任意一种疾病的药物,其特征在于,所述药物以NADPH为活性成分,向NADPH中加入常规辅料按照常规工艺制成临床上可接受的合剂、胶囊剂、片剂、药膜剂、喷雾剂。
- 一种用于保护血管内皮细胞、维护血管正常通透性的药物,其特征在于,所述药物以NADPH为活性成分,向NADPH中加入常规辅料按照常规 工艺制成临床上可接受的合剂、胶囊剂、片剂、药膜剂、喷雾剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510086547.2A CN104840478A (zh) | 2015-02-17 | 2015-02-17 | Nadph在制备治疗心脑血管疾病的药物中的应用 |
CN201510086547.2 | 2015-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016131321A1 true WO2016131321A1 (zh) | 2016-08-25 |
Family
ID=53840727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/095392 WO2016131321A1 (zh) | 2015-02-17 | 2015-11-24 | Nadph在制备治疗心脑血管疾病的药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104840478A (zh) |
WO (1) | WO2016131321A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840478A (zh) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Nadph在制备治疗心脑血管疾病的药物中的应用 |
CN105250326A (zh) * | 2015-10-22 | 2016-01-20 | 苏州人本药业有限公司 | Nadph在制备抗血小板凝集药物中的应用 |
CN105998048A (zh) * | 2016-05-13 | 2016-10-12 | 重庆纳德福实业集团股份有限公司 | 一种治疗缺血性脑中风的药物组合物及其制备方法与用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
CN103340890A (zh) * | 2013-06-08 | 2013-10-09 | 苏州人本药业有限公司 | Nadph作为制备用于防治脑缺血性中风药物方面的应用 |
CN104840478A (zh) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Nadph在制备治疗心脑血管疾病的药物中的应用 |
-
2015
- 2015-02-17 CN CN201510086547.2A patent/CN104840478A/zh active Pending
- 2015-11-24 WO PCT/CN2015/095392 patent/WO2016131321A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945452A (en) * | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
CN103340890A (zh) * | 2013-06-08 | 2013-10-09 | 苏州人本药业有限公司 | Nadph作为制备用于防治脑缺血性中风药物方面的应用 |
CN104840478A (zh) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Nadph在制备治疗心脑血管疾病的药物中的应用 |
Non-Patent Citations (2)
Title |
---|
LIU, JIANBIN ET AL.: "Protective Effects of NADH on Cardiac Fibroblasts Apoptosis Induced by Hydrazine", MEDICAL JOURNAL OF CHINESE PEOPLE'S LIBERATION ARMY, vol. 33, no. 3, 31 March 2008 (2008-03-31), pages 305 - 306 * |
MA, HAIFENG ET AL.: "The Effect of Coenzyme NADH on Biochemical of Myocardial Ischemia Reperfusion Injury in Rats", ACTA ACADEMIAE MEDICINAE WEIFANG, no. 1, 31 January 2009 (2009-01-31), pages 29 - 32, ISSN: 1004-3101 * |
Also Published As
Publication number | Publication date |
---|---|
CN104840478A (zh) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yi et al. | Asiatic acid alleviates myocardial ischemia-reperfusion injury by inhibiting the ROS-mediated mitochondria-dependent apoptosis pathway | |
JP2010535158A (ja) | S−アリルシステインまたはそのアナローグの使用およびそれらの医薬組成物 | |
JP2021091712A (ja) | 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用 | |
WO2014180238A1 (zh) | 一种抗缺氧的药物组合物及其应用 | |
CN101230003B (zh) | 一种丹参丹酚酸a的制备方法 | |
WO2016131321A1 (zh) | Nadph在制备治疗心脑血管疾病的药物中的应用 | |
US8673370B2 (en) | Method of improving cardiovascular health | |
US20090036527A1 (en) | Therapeutic Application Of Leonurine In Treating Cardiomyopathy | |
WO2016131320A1 (zh) | Nadph在制备治疗心脏疾病药物中的应用 | |
CN107158008B (zh) | 一种治疗心肌梗死的药物组合物 | |
US9034398B2 (en) | Traditional Chinese drug comprising Danshen extracts and Sanqi extracts and use thereof | |
CN107213160B (zh) | Nadph在拮抗药物致线粒体毒性中的应用 | |
CN104138376A (zh) | 一种提高缺氧耐受力的缓释剂 | |
CN101070338A (zh) | 丹参酮ⅱa磺酸钾用于制备预防和治疗心肌缺血缺氧、脑缺血缺氧的药物 | |
WO2009135423A1 (zh) | 治疗心脑血管疾病的药物组合物及其制备方法和药盒 | |
CN112209834B (zh) | 一种有机亚硝酸根供体及其制备方法与医药用途 | |
CN112755015A (zh) | Pt2385在制备防治肺动脉高压的药物中的应用 | |
CN101696166B (zh) | 一种丹参丹酚酸a的制备方法 | |
JP6153838B2 (ja) | 血管透過性抑制剤 | |
CN110051671B (zh) | 马齿苋酰胺e用于制备治疗缺血性心脏病的药物的用途 | |
WO2022165794A2 (zh) | 一种抑制肿瘤干细胞的方法及调控肿瘤血管正常化的方法 | |
WO2018094640A1 (zh) | 草质素或其组合物在制备防治心脑血管疾病药物中的应用 | |
CN116370639A (zh) | Glo I激动剂在心肌缺血及再灌注心肌损伤中的药物应用 | |
CN109125308A (zh) | 秋水仙碱在预防和治疗缺血性脑血管疾病的新用途 | |
RU2345761C2 (ru) | Применение каурановых соединений в производстве медикаментов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15882460 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15882460 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 17/01/2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15882460 Country of ref document: EP Kind code of ref document: A1 |